Patents by Inventor FANGQIANG TANG

FANGQIANG TANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TO TNFR2 AND USES THEREOF
    Publication number: 20240067740
    Abstract: The present disclosure provides antibodies and antibody fragments thereof that bind to human TNFR2. The disclosed antibodies, inhibit the TNF-TNFR2 signaling axis and enhance cytokine secretion in T effector cells and are therefore useful for the treatment of cancer, either alone or in combination with other agents.
    Type: Application
    Filed: December 30, 2021
    Publication date: February 29, 2024
    Inventors: Yi PEI, Haichun HUANG, Ming LEI, Han LI, Chi Shing SUM, Alla PRITSKER, Bor-Ruei LIN, Fangqiang TANG
  • Compound having anti-cancer effect, and preparation method therefor and use thereof
    Patent number: 11712434
    Abstract: The present invention provides a compound of the formula I, a process for its preparation and the use of a medicament for the treatment of cancer. The compound of the present invention has an inhibitory effect on various cancer cells and can be biologically converted into the active drug Linifanib in vitro (in plasma) to inhibit the proliferation of tumor cells, especially liver cancer cells, at a lower dose.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 1, 2023
    Assignee: 3D MEDICINES (BEIJING) CO., LTD.
    Inventors: John Gong, Yihui Lin, Fengqing Li, Fangqiang Tang
  • Compound having anticancer activity and preparation method and application
    Patent number: 11351151
    Abstract: The present invention provides a compound exemplified by Formula I: a process for its preparation and the use of a medicament for the treatment of cancer. The compound of the present invention has an inhibitory effect on various cancer cells and can be biologically converted into the active drug Linifanib in vitro (in liver homogenate and spleen homogenate) to inhibit the proliferation of tumor cells, especially liver cancer cells, at a lower dose.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: June 7, 2022
    Assignee: 3D MEDICINES (BEIJING) CO., LTD.
    Inventors: John Gong, Yihui Lin, Fengqing Li, Fangqiang Tang
  • COMPOUND HAVING ANTICANCER ACTIVITY AND PREPARATION METHOD AND APPLICATION
    Publication number: 20200038371
    Abstract: The present invention provides a compound of the formula I, a process for its preparation and the use of a medicament for the treatment of cancer. The compound of the present invention has an inhibitory effect on various cancer cells and can be biologically converted into the active drug Linifanib in vitro (in liver homogenate and spleen homogenate) to inhibit the proliferation of tumor cells, especially liver cancer cells, at a lower dose.
    Type: Application
    Filed: November 17, 2017
    Publication date: February 6, 2020
    Applicant: 3D Medicines (Beijing) Co., Ltd.
    Inventors: JOHN GONG, YIHUI LIN, FENGQING LI, FANGQIANG TANG
  • COMPOUND HAVING ANTI-CANCER EFFECT, AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20190365711
    Abstract: The present invention provides a compound of the formula I, a process for its preparation and the use of a medicament for the treatment of cancer. The compound of the present invention has an inhibitory effect on various cancer cells and can be biologically converted into the active drug Linifanib in vitro (in plasma) to inhibit the proliferation of tumor cells, especially liver cancer cells, at a lower dose.
    Type: Application
    Filed: November 17, 2017
    Publication date: December 5, 2019
    Applicant: 3D MEDICINES (BEIJING) CO., LTD.
    Inventors: JOHN GONG, YIHUI LIN, FENGQING LI, FANGQIANG TANG